18 results about "Necrotizing enterocolitis" patented technology

The present invention provides stable, pure and potent compositions optimized for administration to neonates and / or preterm infants, and use of the same in methods for treating intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), and / or chronic lung disease of prematurity (CLD), comprising administering to a subject in need of treatment a pharmaceutical composition comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and a polysorbate 20 surfactant at high effective doses in low volumes in an infant resulting high serum IGF-1 exposure and treatment of IVH, BPD and / or CLD. In some aspects, provided herein are methods for manufacturing the compositions comprising a single-use bag, wherein the compositions have improved stability, reduced oxidation and increased potency. In some aspects, the methods provided result in reduced incidence of symptoms and features of intraventricular hemorrhage, bronchopulmonary dysplasia, right ventricular hypertrophy (RVH), pulmonary hypertension (PH), necrotizing enterocolitis, or chronic lung disease of prematurity.

Provided herein are methods and probiotic compositions for treating or preventing a disease or neurodevelopmental deficiency in a subject in need thereof using the compositions. Aspects and embodiments of this technology combine the health benefits of probiotic bacteria with prebiotic substances to help stimulate the exclusive growth of the probiotic species and, in one aspect, provide the bacteria in the form of a biofilm on a biocompatible microsphere.

This invention belongs to the field of microbial technology, specifically disclosing a probiotic composition and its application. The probiotic composition provided by this invention includes at least two of the following: prebiotics, vitamin K, and zinc, as well as *Bifidobacterium longum* subsp. infantis i18. The probiotic composition provided by this invention can not only effectively promote the growth and development of premature mice, but also optimize the intestinal flora structure and promote intestinal development in premature infants by reducing the abundance of harmful bacteria and increasing the relative abundance of beneficial bacteria; simultaneously, it can downregulate the levels of pro-inflammatory factors TNF-α and IL-6, reducing intestinal inflammation and lowering the risk of necrotizing enterocolitis in premature infants. This invention can be applied to the preparation of products that improve the intestinal flora of premature infants, promote their growth, or prevent intestinal inflammation.

This invention discloses a strain of *Bacillus belyceae* with broad-spectrum antibacterial activity and its application in the prevention and treatment of necrotic enteritis in poultry. The *Bacillus belyceae* strain provided by this invention (… Bacillus from Velez The genome of strain GDG25CB056 is approximately 3.91 Mb in size, contains no virulence factors, and is rich in gene clusters encoding non-ribosomal peptides and polyketide synthases. Studies have confirmed that this strain exhibits significant growth advantages, strong tolerance to high temperatures, gastric acid, and bile salts, which facilitates intestinal colonization. It can produce siderophores and various enzymes, and has overcome the technical bottleneck of a narrow antibacterial spectrum, possessing broad-spectrum antibacterial activity, especially strong specific antagonistic activity against Clostridium perfringens. In vivo experiments have shown that this strain can significantly reduce the Clostridium perfringens load in the cecum of chicks with necrotizing enterocolitis, alleviate intestinal congestion and swelling, repair damaged intestinal villi, and enhance mucosal barrier function, providing a safe and efficient strain resource for the prevention and treatment of bacterial enteric diseases.

The invention relates to the field of infant food, in particular to an anti-oxidative stress composition and application thereof to improvement of neonatal necrotizing enterocolitis. The composition is prepared from the following components: neutral oligosaccharide and sialylated oligosaccharide. The neutral oligosaccharide is 3-fucosyllactose, and the sialylated oligosaccharide is 3 '-sialic acid lactose. The invention provides a composition capable of relieving neonatal necrotizing enterocolitis. Through combination of the 3-fucosyllactose and the 3 '-sialic acid lactose, related symptoms of the neonatal necrotizing enterocolitis can be improved by inhibiting a TLR4 / NF-kappa B inflammation pathway, improving cell oxidative stress, protecting cell barriers and reducing cell apoptosis, and the 3-fucosyllactose and the 3'-sialic acid lactose have important application value in the field of functional foods or formula foods.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

To provide a bifunctional degrading agent for interleukin-1 receptor-related kinases and its therapeutic use. [Solution] This disclosure provides a bifunctional compound as an IRAK4 degradation agent via the ubiquitin-proteasome pathway, and a method for treating diseases modulated by IRAK4. The compounds of this disclosure or their pharmaceutical compositions are useful as therapeutic agents for treating inflammatory disorders such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, necrotizing enterocolitis, gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases including chronic kidney disease and diabetic kidney disease.

The invention belongs to the technical field of biology, and particularly relates to a biomarker for auxiliary screening of neonatal necrotizing enterocolitis and application of the biomarker. According to the present invention, with the research using the primary bile acid and the secondary bile acid as the newborn necrotizing enterocolitis auxiliary screening marker, the results show that the primary / secondary bile acid ratio is combined with the clinical characteristics such as sex, gestational age, feeding type, fecal occult blood test and the like, the screening efficiency on the NEC is significantly improved, and the AUC value is 0.95; the primary / secondary bile acid ratio is obviously lower than that of NEC sick children in a non-surgical group in the plasma of the NEC sick children in the surgical group, and the screening efficiency of the primary / secondary bile acid ratio on the surgical NEC is (AUC = 0.91, 95% CI = 0.80-1.00); the result proves that the ratio of the primary bile acid to the secondary bile acid can be used as a new biomarker for NEC diagnosis. By adopting the technical means provided by the invention, the screening efficiency is high, the specificity and the sensitivity are relatively high, and the clinical problem that the selection of the operation opportunity of the NEC child patient in the neonatal surgery is lack of a clear objective index is solved.

The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).

The application discloses application of anti-myosin autoantibody in preparation of a diagnosis product for neonatal necrotizing enterocolitis. The application determines that IgG and IgM type anti-myosin autoantibody in peripheral blood of a child with neonatal necrotizing enterocolitis (NEC) is significantly increased in early stage of the disease; the application finds that the anti-myosin autoantibody can be used as an early prediction and diagnosis marker, and is used for diagnosis of NEC; the marker has high diagnosis efficiency for early NEC, and provides an effective basis for early prediction and diagnosis of NEC.

The invention belongs to the technical field of biological medicines, and relates to application of nicotinic acid in preparation of a medicine for preventing and treating neonatal necrotizing enterocolitis. In-vivo experiments prove that the nicotinic acid can enhance the immunosuppression function of myeloid-derived suppressor cells, so that the excessive inflammatory reaction of intestinal tracts of neonatal necrotizing enterocolitis model mice is inhibited, and necrotizing enterocolitis is relieved; nicotinic acid is a vitamin necessary for a human body, the safety advantage of nicotinic acid is far better than that of a brand new chemical synthesis medicine, and the risk and cost of clinical transformation are reduced.

Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool / fecal samples from premature newborns / babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and / or treating necrotizing enterocolitis in infants and young children.

The invention provides an application of ribosome small subunit protein RPS29 in diagnosis of neonatal necrotizing enterocolitis. Research finds that the expression level of the RPS29 protein in a biological sample of a neonatal necrotizing enterocolitis patient is remarkably reduced compared with that of a control neonatal. A further ROC curve analysis result shows that the RPS29 protein can be used as a specific detection marker of the neonatal necrotizing enterocolitis for assisting diagnosis of the neonatal necrotizing enterocolitis, and early diagnosis and early treatment of the neonatal necrotizing enterocolitis can be realized.

Disclosed herein are methods, devices, and systems for accurately detecting and / or diagnosing a child having or at risk of developing necrotizing enterocolitis (NEC). In most embodiments, the child is currently suffering from congenital heart disease (CHD). The disclosed methods, devices, and systems may be useful in monitoring the administration and / or response to therapy for CHD and / or NEC. The disclosed methods, devices, and systems may involve detecting one or more biomarkers in a sample from the child, for example a plasma sample, wherein the sample is less than or equal to about 20 microliters.

The invention relates to the technical field of intelligent medical instruments, in particular to a newborn abdomen monitoring system which comprises a monitoring belt. The multi-source data monitoring module comprises an abdominal circumference measurer, a microphone, an optical probe, a strain sensor, a body temperature sensor and a micro-crack conductive sensor and is used for collecting multi-source data of the newborn; the transmission module is connected with the multi-source data monitoring module and is used for transmitting the multi-source data to a monitoring device; the monitoring device is used for obtaining a monitoring result based on the multi-source data; and the cloud server is connected with the monitoring device and is used for receiving the monitoring result, predicting the risk level of the necrotizing enterocolitis of the newborn based on the monitoring result, and effectively predicting the risk level of the necrotizing enterocolitis of the newborn by collecting the multi-source data of the newborn, so that the monitoring effect is improved.

The present invention relates to a composition comprising at least one human milk oligosaccharide and / or a precursor thereof, for use in preventing and / or treating necrotizing enterocolitis in infants or young children born by C-section.